China Medical System's Drug Granted Clinical Trials Approval; Shares Up Nearly 7%
MT Newswires
Feb 02
China Medical System's (SGX:8A8) drug, CMS-D017, secured a clinical trials approval in China by the National Medical Products Administration, according to a Friday filing with the Singapore Exchange.
Shares of the medical solutions company surged nearly % in Monday trading.
Following the approval, the company will commence clinical trials in China to evaluate the safety, efficacy and other characteristics of the drug.
The trial is seen as crucial in the group's efforts to enhance its capabilities in nephrology.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.